scholarly journals High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer

2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Lin Tan ◽  
Ling Sha ◽  
Ning Hou ◽  
Mei Zhang ◽  
Qian Ma ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Prognostic Value ◽  
Pathological Grade ◽  
P53 Expression ◽  
Node Metastasis

Abstract Objectives: The present study investigated the correlation between α B-crystallin (CRYAB, HSPB5) and p53 expression in ovarian cancer and further analyzed the relationship between their expression and clinicopathology and the prognostic value of their co-expression in ovarian cancer. Methods: CRYAB and p53 expression was assessed using immunohistochemistry on ovarian cancer tumor tissues from 103 cases and validated in an independent group of 103 ovarian cancer patients. Results: High CRYAB and p53 expression rates in ovarian cancer tissues were 61.17% (63/103) and 57.28% (59/103), respectively, and their expression was positively correlated (r = 0.525, P=0.000). High CRYAB expression was significantly correlated with tumor size (P=0.028), lymph node metastasis (P=0.000), distant metastasis (P=0.005), tumor node metastasis (TNM) stage (P=0.002), and survival (P=0.000), while high p53 expression was significantly correlated with tumor size (P=0.006), pathological grade (P=0.023), lymph node metastasis (P=0.001), and survival (P=0.000). Further studies found that the high CRYAB and p53 co-expression was also significantly correlated with pathological grade (P=0.024), lymph node metastasis (P=0.000), Distant metastasis (P=0.015), TNM stage (P=0.013), and survival (P=0.000). High expression of either CRYAB or p53 and high co-expression of CRYAB and p53 were significantly correlated with poor disease-free survival (DFS) and overall survival (OS), respectively (P<0.05). Patients with high CRYAB and p53 co-expression had the worst prognoses among the groups. In addition, multivariate Cox regression models showed that high expression of either CRYAB or p53 and high co-expression of CRYAB and p53 were independent prognostic factors for DFS and OS (P<0.05). Moreover, the positive correlation and prognostic value of CRYAB and p53 expression were verified in another independent dataset. Conclusions: We demonstrated that patients with high CRYAB and p53 co-expression in ovarian cancer have significantly increased risks of recurrence, metastasis, and death compared with other patients. Therefore, more frequent follow-up of patients with high CRYAB and p53 co-expression is required. Our results also suggest that combination therapy with CRYAB inhibitors and p53 blockers may benefit future treatment of ovarian cancer patients with high co-expression of CRYAB and p53.

scholarly journals Prognosis assessment of CD44+/CD24- in Breast Cancer Patients: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Jingjing Gu ◽  
Dandan Chen ◽  
Zhiqiang li ◽  
Yongliang Yang ◽  
Zhaoming Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Clinical Prognosis ◽  
Node Metastasis

Abstract Purpose: This meta-analysis investigated the relationships between the CD44+/CD24- phenotype and tumor size, lymph node metastasis, distant metastasis, disease-free survival (DFS), and overall survival (OS) in 8036 postoperative breast cancer patients enrolled in 23 studies.Methods: A literature search of PubMed, Medline, Cochrane, Embase, and PMC was conducted to identify eligible studies. The combined odds ratios (ORs) and 95% confidence intervals (95%CIs) were analyzed to evaluate the relationships between the CD44+/CD24- phenotype and the pathological and biological characteristics of breast cancer patients, and the combined hazard ratios (HRs) and 95% CIs were calculated to evaluate the relationships between CD44+/CD24- and DFS and OS of breast cancer petients using Stata12.0 software.Results: The CD44+/CD24- phenotype were not related to the tumor size (tumor size > 2.0 cm vs ≤ 2.0 cm, combined OR = 0.98, 95%CI: 0.68–1.34, p = 0.792) and didn’t promote lymph node metastasis (lymph node metastasis vs. no lymph node metastasis, combined OR = 0.94, 95% CI: 0.71–1.26, p = 0.692) and distant metastasis (distant metastasis vs no distant metastasis, combined OR = 3.88, 95% CI: 0.93–16.24, p = 0.064). The CD44+/CD24- phenotype was negatively correlated with postoperative DFS (HR = 1.67, 95% CI: 1.35–2.07, p <0.00001) and OS (combined HR = 1.52, 95%CI: 1.21–1.91, p = 0.0004).Conclusion: These results suggested expression of the CD44+/CD24- phenotype can be used as a reliable indicator of clinical prognosis and a potential therapeutic targets in breastcancer patients.

scholarly journals The role of microvessel density, lymph node metastasis, and tumor size as prognostic factors of distant metastasis in colorectal cancer

2017 ◽  
Vol 13 (6) ◽  
pp. 4327-4333 ◽  
Author(s):  
Tomonari Cho ◽  
Eisuke Shiozawa ◽  
Fumihiko Urushibara ◽  
Nana Arai ◽  
Toshitaka Funaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Distant Metastasis ◽  
Microvessel Density ◽  
Tumor Size ◽  
Node Metastasis

scholarly journals Development of Nomograms for Predicting Lymph Node Metastasis and Distant Metastasis in Newly Diagnosed T1-2 Non-Small Cell Lung Cancer: A Population-Based Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yiming Qi ◽  
Shuangshuang Wu ◽  
Linghui Tao ◽  
Yunfu Shi ◽  
Wenjuan Yang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastasis

BackgroundFor different lymph node metastasis (LNM) and distant metastasis (DM), the diagnosis, treatment and prognosis of T1-2 non-small cell lung cancer (NSCLC) are different. It is essential to figure out the risk factors and establish prediction models related to LNM and DM.MethodsBased on the surveillance, epidemiology, and end results (SEER) database from 1973 to 2015, a total of 43,156 eligible T1-2 NSCLC patients were enrolled in the retrospective study. Logistic regression analysis was used to determine the risk factors of LNM and DM. Risk factors were applied to construct the nomograms of LNM and DM. The predictive nomograms were discriminated against and evaluated by Concordance index (C-index) and calibration plots, respectively. Decision curve analysis (DCAs) was accepted to measure the clinical application of the nomogram. Cumulative incidence function (CIF) was performed further to detect the prognostic role of LNM and DM in NSCLC-specific death (NCSD).ResultsEight factors (age at diagnosis, race, sex, histology, T-stage, marital status, tumor size, and grade) were significant in predicting LNM and nine factors (race, sex, histology, T-stage, N-stage, marital status, tumor size, grade, and laterality) were important in predicting DM(all, P&lt; 0.05). The calibration curves displayed that the prediction nomograms were effective and discriminative, of which the C-index were 0.723 and 0.808. The DCAs and clinical impact curves exhibited that the prediction nomograms were clinically effective.ConclusionsThe newly constructed nomograms can objectively and accurately predict LNM and DM in patients suffering from T1-2 NSCLC, which may help clinicians make individual clinical decisions before clinical management.

scholarly journals Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer

2019 ◽  
Vol 18 ◽  
pp. 153303381989680
Author(s):  
Hongxiao Chen ◽  
Xiufang Tian ◽  
Yajing Luan ◽  
Hui Lu
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Distant Metastasis ◽  
Critical Region ◽  
Noncoding Rna ◽  
Digeorge Syndrome ◽  
Region Gene ◽  
Node Metastasis

Emerging evidence have indicated that dysregulated long noncoding ribonucleic acids act as a novel diagnostic and therapeutic target in the progression of ovarian cancer. Long noncoding RNA DiGeorge syndrome critical region gene 5 has been reported to participate in some types of human cancer progresses, but its clinical roles in ovarian cancer had been rarely reported. This study aimed to explore the expression, clinicopathological features, diagnostic, and prognostic values of DiGeorge syndrome critical region gene 5 in ovarian cancer. The total levels of DiGeorge syndrome critical region gene 5 transcript variant 1 (NR_002733.2) and 2 (NR_045121.1) in patients with ovarian cancer were determined by quantitative reverse transcription polymerase chain reaction. The correlation of DiGeorge syndrome critical region gene 5 expression with clinicopathological factors was statistically analyzed by χ2 test. Overall survival analysis was carried out with the Kaplan–Meier curves with the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify the prognostic significance of DiGeorge syndrome critical region gene 5 expression. Receiver operating characteristic curves were constructed to estimate the diagnostic and prognostic usefulness of DiGeorge syndrome critical region gene 5 in ovarian cancer. Results showed that relative DiGeorge syndrome critical region gene 5 expression was reduced by 36.81% and 65.79% in ovarian cancer tissues of patients and Gene Expression Omnibus DataSets (GSE119056) in contrast to normal tissues, respectively. Patients with lymph node metastasis and distant metastasis exhibited lower levels of DiGeorge syndrome critical region gene 5 in contrast to those patients with non-lymph node metastasis and non-distant metastasis, respectively. Low expression of DiGeorge syndrome critical region gene 5 was significantly associated with large tumor size, more lymph node metastasis, present distant metastasis, advanced clinical stage, and short overall survival in patients with ovarian cancer. Low expression of DiGeorge syndrome critical region gene 5 was an independent unfavorable prognostic factor for overall survival in patients with ovarian cancer. Receiver operating characteristics curves for prognosis yielded significant area under curves for lymph node metastasis, clinical stage, and overall survival. In conclusion, our study demonstrated that downregulated DiGeorge syndrome critical region gene 5 may be a new promising biomarker for predicting clinical progression and prognosis in patients with ovarian cancer.

scholarly journals Effects of Concentrated Growth Factor and Cervical Lymph Node Metastasis on the Prognosis of Mucoepidermoid Carcinoma of the Parotid Gland

2020 ◽  
Vol 4 (1) ◽  
pp. 45-50
Author(s):  
Shang-Zhi Han ◽  
Xin Lv ◽  
Xi-Bo Chen ◽  
Ying-Ying Xu ◽  
Rui Liu ◽  
...  
Keyword(s):  
Lymph Node ◽  
Survival Rate ◽  
Lymph Node Metastasis ◽  
Parotid Gland ◽  
Distant Metastasis ◽  
Mucoepidermoid Carcinoma ◽  
Cervical Lymph Node Metastasis ◽  
Pathological Grade ◽  
Node Metastasis ◽  
Independent Risk Factors

Introduction: Mucoepidermoid carcinoma (MEC) is a common salivary gland malignancy. As studies reported on large cases of mucoepidermoid carcinoma of the parotid glands are few, this paper aims to research the effects of clinical and pathological factors, such as applying concentrated growth factor (CGF) on repairing and cervical lymph node metastasis, on the prognosis of mucoepidermoid carcinoma of the parotid gland. Methods: The retrospective analysis of prognostic factors was conducted based on 176 cases with mucoepidermoidcarcinoma of the parotid gland, who received treatment at the Affiliated Hospital of  Chengde Medical College during the period of March 2000 to March 2012. Results: The Five-year overall survival rate was 75.57%, while the Five-year tumor-free survival rate was 64.77%. Univariate analysis showed that the influential factors for the prognosis of mucoepidermoid carcinoma of the parotid gland included surgical approach, tumor size, clinical stage, pathological grade, lymph node metastasis, and distant metastasis, etc; among which pathological grade, lymph node metastasis, and distant metastasis were indicated by multivariate analysis to be the independent risk factors. Conclusion: The survival rate of mucoepidermoid carcinoma of the parotid gland is relatively high. Lymph node metastasis, pathological grade, and distant metastasis are the independent risk factors that affect the prognosis of patients with mucous epidermis carcinoma of the parotid gland.

Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients

2008 ◽  
Vol 134 (11) ◽  
pp. 1229-1235 ◽  
Author(s):  
Sebastian Mayer ◽  
Axel zur Hausen ◽  
Dirk Otto Watermann ◽  
Stefan Stamm ◽  
Markus Jäger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Node Metastasis ◽  
Soluble Cd44

scholarly journals The prognostic value of tumor size in penile cancer: A Surveillance,Epidemiology, and End Results database study

2020 ◽  
Author(s):  
Wenwen Zheng ◽  
Zhiyu Zhang ◽  
Xilei Xie ◽  
Weiwei Zhu ◽  
Kangqi Li ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Logistic Regression Analysis ◽  
Tumor Size ◽  
Prognostic Value ◽  
Penile Cancer ◽  
Node Metastasis ◽  
End Results

Abstract Background: The objective of this study was to investigate the prognostic value of tumor size on cancer-specific mortality (CSM) and lymph node metastasis for patients with penile squamous cell carcinoma (PSCC).Method: The patients diagnosed with PSCC between 2004 and 2015 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Restricted cubic spline functions were calculated to characterize the association between tumor size and the risk of CSM. The competing-risks model was used to evaluate the impact of tumor size on the cumulative incidence of CSM. The logistic regression analysis was performed to examine the association between tumor size and lymph node metastasis.Results: Totally, 1365 PSCC patients were analyzed, with 52.3% having tumors ≤30 mm, and 47.7% >30 mm. The restricted cubic splines showed that the risks of CSM increased as tumors enlarged. Following adjustment of competing events, the PSCC patients with tumors >30 mm were more likely to succumb to CSM in comparison with those with tumors ≤30 mm (hazard ratio [HR]=1.57, 95% confidence interval [CI]: 1.23-2.01, P<0.001). In subgroup analyses, tumor size >30 mm was significantly associated with an increased risk of CSM relative to tumor size ≤30 mm among patients with T1 (HR=1.56, 95%CI: 1.03-2.37, P=0.036) and T3 (HR=2.51, 95%CI: 1.41-4.45, P=0.002) classifications. On logistic regression analysis, tumors >30 mm were significantly associated with lymph node metastasis (odds ratio [OR]=1.46, 95% CI: 1.03-2.07, P=0.034).Conclusion: Larger tumors (>30 mm) were significantly associated with higher risks of CSM and increased likelihood of lymph node metastasis for PSCC patients, which could be integrated into the development of a staging system for penile cancer.

Sign in / Sign up

Export Citation Format

Share Document